$-0.87 EPS Expected for PTC Therapeutics, Inc. (PTCT)

October 13, 2017 - By Clifton Ray

 $ 0.87 EPS Expected for PTC Therapeutics, Inc. (PTCT)
Investors sentiment decreased to 0.92 in 2017 Q2. Its down 0.24, from 1.16 in 2017Q1. It worsened, as 17 investors sold PTC Therapeutics, Inc. shares while 34 reduced holdings. 17 funds opened positions while 30 raised stakes. 31.07 million shares or 6.35% more from 29.21 million shares in 2017Q1 were reported.
Wells Fargo Mn reported 53,725 shares stake. Alliancebernstein Limited Partnership has invested 0% in PTC Therapeutics, Inc. (NASDAQ:PTCT). J Goldman Limited Partnership, New York-based fund reported 14,680 shares. Fisher Asset Management Limited owns 0% invested in PTC Therapeutics, Inc. (NASDAQ:PTCT) for 89,642 shares. Oppenheimer And Company holds 0.02% or 42,593 shares. 763 are owned by Royal Retail Bank Of Canada. Pinnacle Associates Limited has 0.12% invested in PTC Therapeutics, Inc. (NASDAQ:PTCT). Great West Life Assurance Communications Can accumulated 4,580 shares. Venbio Select Advisor Limited Co holds 120,000 shares or 0.28% of its portfolio. The United Kingdom-based Barclays Public Limited Co has invested 0% in PTC Therapeutics, Inc. (NASDAQ:PTCT). Goldman Sachs Grp reported 227,477 shares. Nationwide Fund Advsrs invested 0% in PTC Therapeutics, Inc. (NASDAQ:PTCT). Swiss Bancshares owns 56,565 shares for 0% of their portfolio. Walleye Trading Ltd Company invested 0% of its portfolio in PTC Therapeutics, Inc. (NASDAQ:PTCT). New York State Common Retirement Fund reported 0% in PTC Therapeutics, Inc. (NASDAQ:PTCT).

Since May 23, 2017, it had 1 buying transaction, and 0 selling transactions for $337,230 activity.

Analysts expect PTC Therapeutics, Inc. (NASDAQ:PTCT) to report $-0.87 EPS on November, 1.They anticipate $0.16 EPS change or 15.53 % from last quarter’s $-1.03 EPS. After having $-0.44 EPS previously, PTC Therapeutics, Inc.’s analysts see 97.73 % EPS growth. The stock increased 0.17% or $0.03 during the last trading session, reaching $17.86. About 528,373 shares traded. PTC Therapeutics, Inc. (NASDAQ:PTCT) has risen 104.51% since October 13, 2016 and is uptrending. It has outperformed by 87.81% the S&P500.

PTC Therapeutics, Inc. (NASDAQ:PTCT) Ratings Coverage

Among 11 analysts covering PTC Therapeutics (NASDAQ:PTCT), 4 have Buy rating, 2 Sell and 5 Hold. Therefore 36% are positive. PTC Therapeutics had 30 analyst reports since July 31, 2015 according to SRatingsIntel. The stock has “Hold” rating by Cowen & Co on Friday, June 30. On Wednesday, February 24 the stock rating was upgraded by Jefferies to “Hold”. The rating was initiated by Citigroup with “Buy” on Tuesday, August 25. RBC Capital Markets maintained PTC Therapeutics, Inc. (NASDAQ:PTCT) on Wednesday, August 9 with “Hold” rating. The rating was upgraded by Credit Suisse to “Outperform” on Monday, November 14. RBC Capital Markets maintained the stock with “Outperform” rating in Friday, July 31 report. The stock of PTC Therapeutics, Inc. (NASDAQ:PTCT) has “Neutral” rating given on Tuesday, July 26 by Credit Suisse. The company was maintained on Wednesday, February 24 by Wedbush. The firm has “Hold” rating given on Thursday, September 14 by RBC Capital Markets. RBC Capital Markets maintained it with “Sector Perform” rating and $13 target in Friday, November 11 report.

PTC Therapeutics, Inc. is a biopharmaceutical company. The company has market cap of $739.21 million. The Firm is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid biology. It currently has negative earnings. The Company’s product pipeline includes Ataluren (Translarna), PTC596 and RG7916.

More notable recent PTC Therapeutics, Inc. (NASDAQ:PTCT) news were published by: Nasdaq.com which released: “PTC Therapeutics, Inc. (PTCT) in Focus: Stock Moves 14.6% Higher” on October 02, 2017, also Fool.com with their article: “Why PTC Therapeutics, Inc. Dropped Today” published on October 03, 2017, Fool.com published: “The Unusual Reason PTC Therapeutics, Inc. Is Bouncing Back Today” on September 29, 2017. More interesting news about PTC Therapeutics, Inc. (NASDAQ:PTCT) were released by: Fool.com and their article: “Here’s Why PTC Therapeutics, Inc. Is Slipping Today” published on September 26, 2017 as well as Marketwatch.com‘s news article titled: “PTC Therapeutics gains after FDA panel votes against drug approval” with publication date: September 28, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.